Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Related to this article
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
2
Positive Topline Results From Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
3
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
4
Phase 2 Clinical Study Initiated: Evaluating NBI-'567 for the Treatment of Adults With Alzheimer Disease
5